Paratek Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Paratek Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Paratek Pharmaceuticals Inc Strategy Report
- Understand Paratek Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Paratek Pharmaceuticals Inc (Paratek) is a biopharmaceutical company that develops and commercializes therapies based on tetracycline chemistry. The company focuses on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. Nuzyra (Omadacycline), the company’s lead product candidate is an USFDA-approved broad-spectrum antibiotic for the treatment of adults with community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections caused by susceptible bacteria. Its other product Seysara (sarecycline) is also an USFDA-approved drug for the treatment of inflammatory acne vulgaris in patients aged nine or older. Omadacycline is also being evaluated for the treatment of female patients with uncomplicated urinary tract infections and acute pyelonephritis. Paratek is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
75 Park Plaza, 4th Floor, Boston, Massachusetts, 02116
Website
www.paratekpharma.com
Telephone
1 617 8076600
No of Employees
268
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$160.3M
Paratek Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Nuzyra (Omadacycline): | - |
| Acute Sinusitis | Nuzyra |
| Acute Bacterial Skin and Skin Structure Infections (Oral and IV) | Seysara |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In July, the company announced a modification to its project BioShield contract with the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of NUZYRA (omadacycline) for post-exposure prophylaxis (PEP) and treatment of pulmonary anthrax. |
| 2023 | Acquisitions/Mergers/Takeovers | In June, the company announced that it is to be acquired by Gurnet Point Capital and Novo Holdings A/S. |
| 2021 | Regulatory Approval | In August, the company secured approval from U.S. Food and Drug Administration (FDA) for NUZYRA for the treatment of infections caused by nontuberculous mycobacteria. |
Competitor Comparison
| Key Parameters | Paratek Pharmaceuticals Inc | Merck & Co Inc | Pfizer Inc | AbbVie Inc | Abbott Laboratories |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Boston | Kenilworth | New York | North Chicago | Abbott Park |
| State/Province | Massachusetts | New Jersey | New York | Illinois | Illinois |
| No. of Employees | 268 | 72,000 | 88,000 | 50,000 | 114,000 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael F. Bigham | Chairman | Executive Board | 2019 | 65 |
| Evan Loh, M.D. | Chief Executive Officer; Director | Executive Board | 2019 | 64 |
| Jonathan Light | Chief Financial Officer | Senior Management | 2024 | - |
| William M. Haskel | Chief Legal Officer; General Counsel; Secretary | Senior Management | 2020 | 62 |
| Adam Woodrow | Chief Commercial Officer; President | Senior Management | 2019 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward